According to a 2014 study by the WHO, 422 million people were diabetic globally, with low to middle income communities being most effected. Additionally, in 2016 diabetes was the 7th leading cause of death globally. This increase in prevalence informs the need for changing the current manufacturing paradigm to develop new treatments and devices in an effort to make insulin more accessible. We aim to develop a manufacturing technology which allows for rapid insulin production at the point-of-care. In doing so, we utilize a variety of different cell-free platforms to express proinsulin and preproinsulin. The expressed product is then subject to an “on-column” conversion process which removes the C-peptide and signal sequence to yield a mature insulin product. This allows for more efficient production of insulin, while also reducing the burden on downstream purification steps. Additionally, when this approach is coupled with the appropriate process analytical technology, an effective and rapid validation of the final product could be achieved for real-time release.

Developments in point-of-care manufacturing of human insulin using cell-free systems

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.